Results 71 to 80 of about 12,907 (206)

Plant dipeptidyl peptidase-IV inhibitors as antidiabetic agents: a brief review [PDF]

, 2018
Diabetes mellitus is an increasing public health problem in the world. Type 2 diabetes is the most common type of diabetes whose complications contribute to its high death rate.
Hongwei Gao, Madina Kabas, Gulmira Turdu, Yingying Jiang   +3 more
core   +1 more source

Screening and analysis of malt pentapeptide DPP-IV inhibitory activity

npj Science of Food
Type 2 diabetes mellitus (T2DM) poses a significant global health burden, with dipeptidyl peptidase-IV (DPP-IV) inhibitors being critical therapeutic targets for its management.
Yi He, Yan Zhang, Pengying Zhang, Jiaying Li, Wannan Li, Weiwei Han   +5 more
doaj   +1 more source

Synthesis and Characterization of Constrained Peptidomimetic Dipeptidyl Peptidase IV Inhibitors:  Amino-Lactam boroAlanines [PDF]

, 2007
We describe here the epimerization-free synthesis and characterization of a new class of conformationally constrained lactam aminoboronic acid inhibitors of dipeptidyl peptidase IV (DPP IV; E.C. 3.4.14.5).
Jack H. Lai (1883839), Wengen Wu (1883827), Sarah E. Poplawski (2182922), James L. Sudmeier (1883845), Yuhong Zhou (2414881), William W. Bachovchin (1883854), Lawrence J. Milo (2182926), Yuxin Liu (505575), David G. Sanford (1883824), Hlaing H. Maw (2654221), Gillian D. Henry (2303200)   +10 more
core   +1 more source

Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor-associated angioedema [PDF]

Angioedema is a potentially life-threatening adverse effect of angiotensin-converting enzyme inhibitors. Bradykinin and substance P, substrates of angiotensin-converting enzyme, increase vascular permeability and cause tissue edema in animals.
Harris, S, Shreevatsa, A, Gainer, JV, Brown, NJ, Byrd, JB, Summar, M, Touzin, K, Adam, A, Putlur, P, Yu, C, Nadeau, J   +10 more
core   +1 more source

Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors. [PDF]

, 2012
Dipeptidyl peptidase IV (DPPIV, DPP4) is a serine protease that releases N-terminal dipeptides. It is a validated drug target for type 2 diabetes and DPPIV inhibitors are currently evaluated for other therapeutic applications. Various assays are used for
Gomez, Nelson, Simon Scharpé, Veerle Matheeussen, De Meester, Ingrid, Matheeussen, Veerle, Van der Veken, Pieter, Nelson Gomez, Jungraithmayr, Wolfgang, Scharpé, Simon, Anne-Marie Lambeir, Gomez Malaver, Nelson, Pieter Van der Veken, Kathleen Mc Entee, McEntee, Kathleen, Lambeir, Anne-Marie, Ingrid De Meester, Wolfgang Jungraithmayr   +16 more
core   +1 more source

Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitors [PDF]

Diabetologia, 2012
To the Editor: The position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recently published an updated algorithm for the initiation and adjustment of therapy for the management of hyperglycaemia in type 2 diabetes [1].
openaire   +2 more sources

A Facile Method for Screening DPP IV Inhibitors in Living Cell System Based on Enzyme Activity Probe

Journal of Analytical Methods in Chemistry
Dipeptidyl peptidase IV (DPP IV), one of the most essential peptidase, is widely distributed in various organs and tissues of the human body, which affects protein stability by acting on peptide bonds at the end of peptide chains and is further involved ...
Shu-Mei Pan, Chun-Yu Xing, Hong-Wei Li, Rui-Min Wang, Xin-Yue Pu, Tie-Gang Wang, Dan-Dan Wang, Li-Wei Zou   +7 more
doaj   +1 more source

Discovery and Structure−Activity Relationships of Piperidinone- and Piperidine-Constrained Phenethylamines as Novel, Potent, and Selective Dipeptidyl Peptidase IV Inhibitors [PDF]

, 2016
Dipeptidyl peptidase IV (DPP4) inhibitors are emerging as a new class of therapeutic agents for the treatment of type 2 diabetes. They exert their beneficial effects by increasing the levels of active glucagon-like peptide-1 and glucose-dependent ...
Zhonghua Pei (1600639), Daisy Pireh (2495497), Kent D. Stewart (1993075), Bradley J. Backes (2495482), David W. A. Beno (2110654), James M. Trevillyan (2495491), Thomas W. von Geldern (2495479), Anita J. Kempf-Grote (2495485), Thomas H. Lubben (1262973), Stephen J. Ballaron (2495488), Hing L. Sham (2126860), Xiaofeng Li (342614), Kenton Longenecker (2495476), Chunqiu Lai (2495494)   +13 more
core   +1 more source

Discovery of non-covalent dipeptidyl peptidase IV inhibitors which induce a conformational change in the active site [PDF]

, 2007
A series of non-covalent inhibitors of the serine protease dipeptidyl peptidase IV (DPP-IV) were found to adopt a U-shaped binding conformation in X-ray co-crystallization studies.
Mohr, Michael, Evers, Britta, Weichert, Andreas G., Mest, Hans-Juergen, Zechel, Johann-Christian, Blaszczak, Larry C., Margolis, Brandon J., Wiley, Michael R., Cauvin, Annick, Pulley, Shon R., Petersen, Soenke, Parsons, Stephen H., Boelke, Andre, Hankotius, Dirk, Kalbfleisch, J. Michael, Watson, Brian M., Klimkowski, Valentine J., Timm, David E., Ruehter, Gerd, Shi, Qing, Dingess-Hammond, Elizabeth A., Canada, Emily J., Wishart, Graham N., Renson, Beatrice, Sheehan, Scott M.   +24 more
core   +1 more source

Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans [PDF]

, 2010
Dipeptidyl peptidase-IV inhibitors improve glucose homeostasis in type 2 diabetics by inhibiting degradation of the incretin hormones. Dipeptidyl peptidase-IV inhibition also prevents the breakdown of the vasoconstrictor neuropeptide Y and ...
Nancy J. Brown, Loretta Byrne, Annis Marney, Siri Kunchakarra   +3 more
core   +1 more source